Published in Oxid Med Cell Longev on March 12, 2017
mTOR signaling in growth control and disease. Cell (2012) 29.21
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 10.16
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med (2008) 9.64
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med (2010) 8.28
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
What does Stat3 do? J Clin Invest (2002) 4.83
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol (2006) 4.24
Tuberous sclerosis. Lancet (2008) 4.24
Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol (2013) 3.49
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol (2013) 3.18
Epidemiology of tuberous sclerosis. Ann N Y Acad Sci (1991) 2.96
mTOR kinase structure, mechanism and regulation. Nature (2013) 2.80
Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci U S A (2011) 2.73
Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med (2008) 2.70
Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med (2011) 2.67
Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res (2011) 2.06
Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev Med Child Neurol (2006) 2.01
Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol (1977) 1.80
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol (2014) 1.74
Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study. Neuroepidemiology (2009) 1.71
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol (2009) 1.70
mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett (2013) 1.40
Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol (2011) 1.34
mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets (2008) 1.33
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology (2013) 1.33
The complexes of mammalian target of rapamycin. Curr Protein Pept Sci (2010) 1.33
mTORC1 signaling: what we still don't know. J Mol Cell Biol (2010) 1.32
Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia (2008) 1.23
mTOR signaling and its roles in normal and abnormal brain development. Front Mol Neurosci (2014) 1.19
Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr (2014) 1.14
Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med (2007) 1.14
New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Curr Top Microbiol Immunol (2010) 1.14
Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol (2014) 1.12
Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg (2008) 1.09
mTOR Inhibitors in Tuberous Sclerosis Complex. Curr Neuropharmacol (2012) 1.09
Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) (2014) 1.07
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant (2015) 1.04
Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol (2009) 1.03
Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J (2013) 1.03
Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc (2009) 1.00
Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. Proc Am Thorac Soc (2010) 0.99
Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol (2013) 0.99
Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant (2008) 0.98
Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM. Autophagy (2011) 0.97
Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle (2013) 0.95
The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol (2016) 0.93
Current management of tuberous sclerosis complex. Paediatr Drugs (2008) 0.91
The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs (2016) 0.90
Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci (Lond) (2015) 0.86
Sirolimus: a new option in transplantation. Expert Opin Pharmacother (2005) 0.84
Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer (2010) 0.83
TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet J Rare Dis (2014) 0.82
Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol (2015) 0.80
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. Ther Adv Urol (2015) 0.79
Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev (2016) 0.77
Everolimus: an immunosuppressive agent in transplantation. Expert Opin Pharmacother (2006) 0.77
Effects of Combining Rapamycin and Resveratrol on Apoptosis and Growth of TSC2-Deficient Xenograft Tumors. Am J Respir Cell Mol Biol (2015) 0.76
Current phase II clinical data for ridaforolimus in cancer. Expert Opin Investig Drugs (2013) 0.76
Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas. Expert Rev Clin Pharmacol (2013) 0.76
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? J Diabetes Res (2015) 0.78
mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging. Oxid Med Cell Longev (2017) 0.75